

**LISTING OF CLAIMS**

1. (Original) A method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof, said method comprising administering a therapeutically effective amount of a composition comprising at least one non-nucleotide or non-protein agent that inhibits expression, signaling or biological functions of connective tissue growth factor (CTGF), and a pharmaceutically acceptable carrier.
2. (Original) The method of claim 1, wherein said administering is by topical application, intracamerally or via an implant.
3. (Original) The method of claim 1, wherein the total concentration of said CTGF inhibitor in said composition is from 0.01% to 2%.
4. (Original) The method of claim 1, wherein said patient suffers from glaucoma or ocular hypertension.
5. (Original) The method of claim 4, wherein said glaucoma is normal-tension glaucoma.
6. (Original) A method for lowering intraocular pressure in a patient in need thereof, said method comprising administering a therapeutically effective amount of a composition comprising at least one non-nucleotide or non-protein agent that inhibits expression, signaling, or biological functions of connective tissue growth factor (CTGF), and a pharmaceutically acceptable carrier.
7. (Original) The method of claim 6, wherein said administering is by topical application, intracamerally or via an implant.
8. (Original) The method of claim 6, wherein the total concentration of said CTGF inhibitor in said composition is from 0.01% to 2%.
9. (Original) The method of claim 6, wherein said patient suffers from glaucoma or ocular hypertension.

10. (Original) The method of claim 9, wherein said glaucoma is normal-tension glaucoma.
11. (Original) A method for preventing the visual field loss associated with Primary Open Angle Glaucoma (POAG), said method comprising administering to a patient in need thereof a composition comprising a non-nucleotide or non-protein agent that modulates the expression of Connective Tissue Growth Factor (CTGF) such that intraocular pressure is controlled and protection is provided to retinal ganglion cells or to the optic nerve head.
12. (Previously Amended) A composition for lowering intraocular pressure and providing neuroprotection in a patient in need thereof, said composition comprising at least one non-nucleotide or non-protein agent that inhibits the expression, signaling, or biological functions of connective tissue growth factor (CTGF) and a pharmaceutically acceptable carrier.
13. (Original) The composition of claim 12, wherein the total concentration of said CTGF inhibitor in said composition is from 0.01% to 2%.
14. (New) The method of claim 1 wherein said agent is selected from the group consisting of:  
  
GW-8510, purvalanol A, roscovitine, troglitazone, ciglitazone, 15(S)HETE, and combinations thereof.
15. (New) The composition of claim 12 wherein said agent is selected from the group consisting of:  
  
GW-8510, purvalanol A, roscovitine, troglitazone, ciglitazone, 15(S)HETE, and combinations thereof.